SCHEMBL195173

SCHEMBL195173

O=C1[CH]CCCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL293677 0.92
SCHEMBL308103 0.80
SCHEMBL541182 0.75
SCHEMBL541181 0.75
SCHEMBL4954677 0.73 ALDH1A1 (0.39)
SCHEMBL29636334 0.73 ALDH1A1 (0.39)
SCHEMBL30545269 0.73 ALDH1A1 (0.39)
SCHEMBL4954670 0.73 ALDH1A1 (0.39)
SCHEMBL4954673 0.73 ALDH1A1 (0.39)
SCHEMBL651905 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 522 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9227955-B2 Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same BORYUNG PHARMACEUTICAL CO., LTD. (KR) 2016-01-05 US claimed
EP-2496084-B1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AERPIO THERAPEUTICS INC (US) 2015-06-10 EP claimed
US-20140309192-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC, 2014-10-16 US claimed
EP-2776407-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2014-09-17 EP claimed
US-20140256711-A1 Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same BORYUNG PHARMACEUTICAL CO., LTD. (KR) 2014-09-11 US claimed
WO-2013070657-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-05-16 WO claimed
US-8309537-B2 Compositions and methods for treating colitis AERPIO THERAPEUTICS INC. (US) 2012-11-13 US claimed
EP-2496084-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS Aerpio Therapeutics Inc. (US) 2012-09-12 EP claimed
US-20120077803-A1 Uses Of NK Receptor Antagonists NOVARTIS AG (CH) 2012-03-29 US claimed
EP-2400953-A1 USES OF NK RECEPTOR ANTAGONISTS Novartis AG (CH) 2012-01-04 EP claimed
WO-2003050088-A1 SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY ELI LILLY AND COMPANY (US) 2003-06-19 WO claimed
EP-0923550-B1 ACYLAMINOALKENYLENE-AMIDE DERIVATIVES AS NK1 AND NK2 ANTAGONISTS NOVARTIS AG (CH) 2002-09-25 EP claimed
US-6319917-B1 NEUROGENIC INFLAMMATION AND TACHYKININ BRONCHOCONSTRICTION INHIBITORS NOVARTIS AG (CH) 2001-11-20 US claimed
WO-2001085696-A1 BUTENOIC ACIDS DERIVATIVES AND THEIR USE IN THE TREATMENT OF RHINITIS NOVARTIS AG (CH) 2001-11-15 WO claimed
WO-2001016116-A1 PROCESS FOR SYNTHESIZING ISOXAZOLINES AND ISOXAZOLES CHEMRX ADVANCED TECHNOLOGIES, INC. (US) 2001-03-08 WO claimed
WO-2001016115-A1 PROCESS FOR SYNTHESIZING ISOXAZOLIDINES CHEMRX ADVANCED TECHNOLOGIES, INC. (US) 2001-03-08 WO claimed
EP-0923550-A1 ACYLAMINOALKENYLENE-AMIDE DERIVATIVES AS NK1 AND NK2 ANTAGONISTS Novartis AG (CH) 1999-06-23 EP claimed
EP-0810991-B1 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS NOVARTIS AG (CH) 1999-04-14 EP claimed
WO-1998007694-A1 ACYLAMINOALKENYLENE-AMIDE DERIVATIVES AS NK1 AND NK2 ANTAGONISTS NOVARTIS AG (CH) 1998-02-26 WO claimed
EP-0213326-B1 2,5-DIMETHYL PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR USE CASSELLA Aktiengesellschaft (DE) 1991-03-06 EP claimed